Artelo Biosciences Secures $310K in Highly Dilutive Bridge Financing Amidst Going Concern

summarizeSummary

Artelo Biosciences obtained $310,000 in bridge financing with highly dilutive conversion terms, including a pre-reverse split conversion price floor, to address its "going concern" status.

check_boxKey Events

• Secured $310,000 in Bridge Financing

  Artelo Biosciences entered into two Securities Purchase Agreements to issue 12% bridge notes, receiving $210,000 from Vanquish Funding Group Inc. and $100,000 from Boot Capital LLC, totaling $310,000 for general working capital.

• Highly Dilutive Conversion Terms

  The notes are convertible into common stock upon an Event of Default at a price that is the greater of $0.125 or 75% of the lowest trading price in the 10 days prior to conversion. The conversion price is explicitly *not* adjusted for the recent reverse stock split, making the $0.125 floor extremely unfavorable and potentially leading to massive dilution.

• Significant Default Penalties

  Upon an Event of Default, the outstanding principal and accrued interest become immediately due at 150% (or 200% for a second default) of the amount, in addition to the conversion rights.

• Follows Going Concern Warning and Reverse Split

  This financing follows the company's recent 1-for-3 reverse stock split (effective March 10, 2026) and the disclosure of a "going concern" matter in its audited financials, highlighting the company's urgent need for capital.

auto_awesomeAnalysis

Artelo Biosciences, facing a "going concern" warning and having recently completed a reverse stock split, secured $310,000 through two bridge notes. While providing immediate working capital, the financing terms are highly unfavorable. The notes carry a 12% interest rate and include significant original issue discounts. Critically, upon an Event of Default, the notes become due at 150% of principal and can be converted into common stock at the greater of $0.125 or 75% of the lowest trading price in the preceding 10 days. The explicit clause stating the conversion price is *not* subject to the recent reverse stock split means the $0.125 floor is based on the pre-split share value, representing an extreme discount to the current stock price and posing a severe dilution risk to existing shareholders if conversion occurs. This type of financing is often associated with distressed companies and can lead to a "death spiral" of dilution.